YAP1 and cancer: Verteporfin was selected as a candidate because (a) the molecular structure of verteporfin is unique (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.137876DS1), and (b) verteporfin was recently reported to be a YAP1 inhibitor with an inhibitory effect on oncogenic growth in various cancers (15, 19, 20).